Parkinson's Disease
Pipeline by Development Stage
Drug Modality Breakdown
Parkinson's Disease is a $3.3B market dominated by a single blockbuster therapy, characterized by mature standard-of-care treatments and emerging pipeline innovation.
Key Trends
- One product (likely levodopa-based or dopamine agonist) commands 76% market share, indicating monopolistic market structure
- Multiple patent cliffs approaching 2026-2033, with $2.8B+ in revenue at risk, creating significant M&A and generic competition pressure
- Active pipeline with 496 trials across all phases, suggesting sustained R&D investment in next-generation dopaminergic and neuroprotective approaches
Career Verdict
This is a stable but consolidating specialty with good job security in commercial roles, though innovators should target the emerging pipeline rather than legacy products facing patent expiration.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | Unknown (76% market share product) | Unknown | $2.5B | 76% | Peak | Stable | |
| 2 | NEUPRO (rotigotine) | UCB Pharma | $93M | 3% | Peak | Stable | 5.8yr |
| 3 | APOKYN (apomorphine hydrochloride) | Sumitomo Dainippon Pharma | $72M | 2% | LOE_Approaching | Declining | |
| 4 | NOURIANZ (istradefylline) | Inpharmus | $50M | 2% | LOE_Approaching | Declining | 1.7yr |
| 5 | INBRIJA (levodopa) | Merz Therapeutics | $27M | 1% | Peak | Stable | 7.5yr |
Drug Class Breakdown
market-defining but undisclosed lead product
niche mechanism
experimental approaches
legacy standard-of-care
emerging mechanism
neuroprotective approach
Career Outlook
StableParkinson's disease represents a stable, well-established specialty with strong commercial infrastructure but limited growth headroom due to market maturity and impending patent cliffs. The $2.8B+ revenue at risk between 2026 and 2033 will create consolidation and restructuring opportunities, particularly in lifecycle management, digital therapeutics, and combination therapy development. Specialists should expect steady hiring in commercial roles but should position themselves in pipeline innovation, patient services, and emerging mechanisms to remain competitive.
Breaking In
Target commercial or clinical operations roles at top-hiring companies (Abbott, Takeda, Amgen) to build core pharma skills while enjoying strong salaries; avoid early-career R&D positions in legacy mechanisms.
For Experienced Professionals
Leverage expertise in mature neurology to move into pipeline roles focused on next-generation dopaminergic or neuroprotective therapies; consider transitioning to emerging mechanisms or biotech with fresher approaches if growth is a priority.
In-Demand Skills
Best For
Hiring Landscape
Parkinson's disease supports 5,510 jobs across the 15-company ecosystem, with hiring concentrated in Commercial (1,151 roles, $246K avg) and Engineering (501 roles, $201K avg), reflecting the mature market's emphasis on commercialization and manufacturing. Top hiring companies include Abbott (1,552 jobs) and Takeda (1,106 jobs), though these appear to be company-wide figures not isolated to PD; Amgen (910 jobs) and Sanofi (813 jobs) suggest neurology is a significant hiring focus. Salary ranges span $112K (Manufacturing) to $246K (Commercial), indicating strong compensation for commercial and clinical roles.
Top Hiring Companies
By Department
Commercial and clinical operations roles command premium salaries ($223K-$246K); entry into R&D or Manufacturing offers lower compensation but stable mid-career growth potential.
On Market (7)
Approved therapies currently available
Competitive Landscape
99 companies ranked by most advanced pipeline stage
+69 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 12,594 patients across 50 trials
Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease
Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease
Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease
The Effect of Donepezil on Gait and Balance in Parkinson's Disease
Multicenter Placebo Controlled Study to Assess the Effect of Rasagiline on Sleep-wake Disturbances in Patients With Parkinson's Disease
Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
Cognitive Decline in Non-demented PD
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off
Study to Evaluate Initiation of Stalevo in Early Wearing-off
Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease
Dopamine Turnover Rate as Surrogate Parameter for Diagnosis of Early Parkinson's Disease
Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease
Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease Patients
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch
Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
A Study of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
Related Jobs in Neurology
Associate Director, Field Medical Affairs-NYC metro area (Neurology)
Associate Director, Field Medical Affairs-Boston (Neurology)
Senior Manager, Field Medical Affairs-Chicago (Neurology)
Associate Director, Field Medical Affairs-Los Angeles (Neurology)
Senior Manager, Field Medical Affairs- Houston/Dallas (Neurology)
Executive Director, Commercial Insights & Analytics - Neurology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.